Kapor Suncica, Santibanez Juan F
Clinical Hospital Center "Dr Dragisa Misovic-Dedinje", Department of Hematology, University of Belgrade, 11000 Belgrade, Serbia.
Molecular Oncology Group, Institute for Medical Research, University of Belgrade, 11000 Belgrade, Serbia.
J Clin Med. 2021 Jun 24;10(13):2788. doi: 10.3390/jcm10132788.
Myeloid malignancies arise from an altered hematopoietic stem cell and mainly comprise acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative malignancies, and chronic myelomonocytic leukemia. Myeloid neoplastic leukemic cells may influence the growth and differentiation of other hematopoietic cell lineages in peripheral blood and bone marrow. Myeloid-derived suppressor cells (MDSCs) and mesenchymal stromal cells (MSCs) display immunoregulatory properties by controlling the innate and adaptive immune systems that may induce a tolerant and supportive microenvironment for neoplasm development. This review analyzes the main features of MDSCs and MSCs in myeloid malignancies. The number of MDSCs is elevated in myeloid malignancies exhibiting high immunosuppressive capacities, whereas MSCs, in addition to their immunosuppression contribution, regulate myeloid leukemia cell proliferation, apoptosis, and chemotherapy resistance. Moreover, MSCs may promote MDSC expansion, which may mutually contribute to the creation of an immuno-tolerant neoplasm microenvironment. Understanding the implication of MDSCs and MSCs in myeloid malignancies may favor their potential use in immunotherapeutic strategies.
髓系恶性肿瘤起源于造血干细胞改变，主要包括急性髓系白血病、骨髓增生异常综合征、骨髓增殖性肿瘤和慢性粒单核细胞白血病。髓系肿瘤性白血病细胞可能影响外周血和骨髓中其他造血细胞谱系的生长和分化。髓系来源的抑制细胞（MDSCs）和间充质基质细胞（MSCs）通过控制先天性和适应性免疫系统表现出免疫调节特性，这可能为肿瘤发展诱导一个耐受和支持性的微环境。本综述分析了髓系恶性肿瘤中MDSCs和MSCs的主要特征。在具有高免疫抑制能力的髓系恶性肿瘤中，MDSCs的数量增加，而MSCs除了其免疫抑制作用外，还调节髓系白血病细胞的增殖、凋亡和化疗耐药性。此外，MSCs可能促进MDSC的扩增，这可能共同促成免疫耐受肿瘤微环境的形成。了解MDSCs和MSCs在髓系恶性肿瘤中的作用可能有利于它们在免疫治疗策略中的潜在应用。
